– Protocols updated to evaluate the benefit of enhanced host conditioning, with further data expected in 2H 2024 – – First three patients dosed in CHIRON and THETIS with enhanced host ...
- Monotherapy data from higher-dose cohorts in both CHIRON and THETIS and combination data from THETIS Cohort B expected in 2H 2022 - “Dosing the first patient in CHIRON with cNeT from our higher-dose ...
LONDON, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL) today announced the discontinuation of its TIL-based cNeT program and closure of the Phase I/IIa CHIRON and THETIS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback